Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children

Arthritis is one of the main manifestations of mixed connective tissue disease (MCTD) and overlap syndrome in children and can be responsible for functional disability. We report on 2 children with arthritis that were dramatically improved by a treatment with interleukin-6 (IL-6) blockers in the con...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabrera, Natalia, Duquesne, Agnes, Desjonquères, Marine, Larbre, Jean-Paul, Lega, Jean-Christophe, Fabien, Nicole, Belot, Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Paediatric Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030575/
https://www.ncbi.nlm.nih.gov/pubmed/27738519
http://dx.doi.org/10.1136/rmdopen-2016-000271
_version_ 1782454702506508288
author Cabrera, Natalia
Duquesne, Agnes
Desjonquères, Marine
Larbre, Jean-Paul
Lega, Jean-Christophe
Fabien, Nicole
Belot, Alexandre
author_facet Cabrera, Natalia
Duquesne, Agnes
Desjonquères, Marine
Larbre, Jean-Paul
Lega, Jean-Christophe
Fabien, Nicole
Belot, Alexandre
author_sort Cabrera, Natalia
collection PubMed
description Arthritis is one of the main manifestations of mixed connective tissue disease (MCTD) and overlap syndrome in children and can be responsible for functional disability. We report on 2 children with arthritis that were dramatically improved by a treatment with interleukin-6 (IL-6) blockers in the context of connective tissue disease. However, in both cases, other systemic autoimmune symptoms were not modified by the treatment and autoantibodies tend to increase, suggesting a differential effect of IL-6 inhibition on articular inflammation and systemic autoimmunity.
format Online
Article
Text
id pubmed-5030575
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50305752016-10-13 Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children Cabrera, Natalia Duquesne, Agnes Desjonquères, Marine Larbre, Jean-Paul Lega, Jean-Christophe Fabien, Nicole Belot, Alexandre RMD Open Paediatric Rheumatology Arthritis is one of the main manifestations of mixed connective tissue disease (MCTD) and overlap syndrome in children and can be responsible for functional disability. We report on 2 children with arthritis that were dramatically improved by a treatment with interleukin-6 (IL-6) blockers in the context of connective tissue disease. However, in both cases, other systemic autoimmune symptoms were not modified by the treatment and autoantibodies tend to increase, suggesting a differential effect of IL-6 inhibition on articular inflammation and systemic autoimmunity. BMJ Publishing Group 2016-09-15 /pmc/articles/PMC5030575/ /pubmed/27738519 http://dx.doi.org/10.1136/rmdopen-2016-000271 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Paediatric Rheumatology
Cabrera, Natalia
Duquesne, Agnes
Desjonquères, Marine
Larbre, Jean-Paul
Lega, Jean-Christophe
Fabien, Nicole
Belot, Alexandre
Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children
title Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children
title_full Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children
title_fullStr Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children
title_full_unstemmed Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children
title_short Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children
title_sort tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children
topic Paediatric Rheumatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030575/
https://www.ncbi.nlm.nih.gov/pubmed/27738519
http://dx.doi.org/10.1136/rmdopen-2016-000271
work_keys_str_mv AT cabreranatalia tocilizumabinthetreatmentofmixedconnectivetissuediseaseandoverlapsyndromeinchildren
AT duquesneagnes tocilizumabinthetreatmentofmixedconnectivetissuediseaseandoverlapsyndromeinchildren
AT desjonqueresmarine tocilizumabinthetreatmentofmixedconnectivetissuediseaseandoverlapsyndromeinchildren
AT larbrejeanpaul tocilizumabinthetreatmentofmixedconnectivetissuediseaseandoverlapsyndromeinchildren
AT legajeanchristophe tocilizumabinthetreatmentofmixedconnectivetissuediseaseandoverlapsyndromeinchildren
AT fabiennicole tocilizumabinthetreatmentofmixedconnectivetissuediseaseandoverlapsyndromeinchildren
AT belotalexandre tocilizumabinthetreatmentofmixedconnectivetissuediseaseandoverlapsyndromeinchildren

Ejemplares similares